Pharmacotherapeutic considerations for elderly patients with colorectal cancer

References

• Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018 Aug 1;36(22):2326–2347. PMID: 29782209.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Older Adult Oncology. Version 1.2019. 2019.
   Google Scholar
• Kotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76. PMID: 19514965.
   PubMed Web of Science ®Google Scholar
• Vincent GK, Velkoff VA. 2010 May. The next four decades the older population in the United States: 2010 to 2050. Current population reports. U.S. Department of Commerce Economics and Statistics Administration, U.S. Census Bureau, pp. 25–1138.
   Google Scholar
• Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American society of clinical oncology statement. J Clin Oncol. 2015 Nov 10;33(32):3826–3833. PMID: 26195697.
   PubMed Web of Science ®Google Scholar
• Loh KP, Soto-Perez-de-Celis E, Hsu T, et al. What every oncologist should know about geriatric assessment for older patients with cancer: young international society of geriatric oncology position paper. J Oncol Pract. 2018 Feb;14(2):85–94. PMID: 29436306.
   PubMed Web of Science ®Google Scholar
• Itatani Y, Kawada K, Sakai Y. Treatment of elderly patients with colorectal cancer. Biomed Res Int. 2018;2018:2176056. PMID: 29713641.
   PubMedGoogle Scholar
• Korc-Grodzicki B. Geriatric oncology education for the oncologist is overdue. J Natl Comp Can Netw. 2018 Mar;16(3):336–338. PMID: 29523672.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: colorectal cancer. [ cited 2019 May 17]. Available from: https://seer.cancer.gov/statfacts/html/colorect.html
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34. PMID: 30620402.
   PubMed Web of Science ®Google Scholar
• Davis LE. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer. Am J Manag Care. 2018;24(7):S107–S117.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Colon Cancer. Version 1.2019. 2019.
   Google Scholar
• 5-Fluorouracil package insert. Irvine, CA: Spectrum Pharmaceuticals, Inc.; 2016 July.
   Google Scholar
• Xeloda (Capecitabine) package insert. South San Francisco, CA: Genentech USA, Inc.; 2019 Feb.
   Google Scholar
• Camptosar (Irinotecan) package insert. NY, NY: Pfizer; 2019 Feb.
   Google Scholar
• Eloxatin (Oxaliplatin) package insert. Bridgewater NJ: Sanofi-Aventis U.S. LLC; 2015 Oct.
   Google Scholar
• Avastin (Bevacizumab) package insert. South San Francisco, CA: Genentech, Inc; 2019 Feb.
   Google Scholar
• Erbitux (Cetuximab) package insert. Indianapolis, IN: Bristol-Myers Squibb; 2019 Apr.
   Google Scholar
• Vectibix (Panitumumab) package insert. Thousand Oaks, CA: Amgen; 2017 June.
   Google Scholar
• Cyramza (Ramucirumab) package insert. Indianapolis, IN: Eli Lilly and Company; 2019 May.
   Google Scholar
• Zaltrap (Ziv-aflibercept) package insert. Bridgewater, NJ: Snofi-Aventis U.S. LLC; 2016 June.
   Google Scholar
• Stivarga (Regorafenib) package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; June 2018.
   Google Scholar
• Lonsurf (Trifluridine-Tiparacil) package insert. Princeton, NJ: Taiho Oncology, Inc; 2019 Feb.
   Google Scholar
• Keytruda (Pembrolizumab) package insert. Whitehouse Station, NJ: Merck and Company, Inc; 2019.
   Google Scholar
• Opdivo (Nivolumab) package insert. Princeton, NJ: Bristol-Myers Squibb; 2019 May.
   Google Scholar
• Yervoy (Ipilimumab) package insert. Princeton, NJ: Bristol-Myers Squibb; 2019 May.
   Google Scholar
• Ursem C, Atreya CE, Van Loon K. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest Cancer. 2018;8:13–23. PubMed Central PMCID: PMCPMC5889076.
   PubMedGoogle Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18(9):1182–1191.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018 Mar 10;36(8):773–779.
   PubMed Web of Science ®Google Scholar
• Takegawa N, Yonesaka K. HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy. Clin Colorectal Cancer. 2017 Dec;16(4):247–251.
   PubMed Web of Science ®Google Scholar
• Lieu CH, Renfro LA, de Gramont A, et al. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD clinical trials program. J Clin Oncol. 2014 September;32(27):2975–2982.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014 Aug 20;32(24):2595–2603. PMID: 25071125.
   Google Scholar
• Lockett J, Sauma S, Radziszewska B, et al. Adequacy of inclusion of older adults in NIH-funded phase III clinical trials. J Am Geriatr Soc. 2019 Jan 29;67: 218–222.
   PubMed Web of Science ®Google Scholar
• Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014 Aug 20;32(24):2587–2594. PMID: 25071116.
   PubMed Web of Science ®Google Scholar
• Singh H, Kanapuru B, Smith C, et al. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration. J Clin Onc. 2017 May 20;35(15):1009.
   Google Scholar
• Canoui-Poitrine F, Lievre A, Dayde F, et al. 1445P inclusion of older patients with colorectal cancer in clinical trials: the SAGE prospective multicenter cohort study. Ann Oncol. 2017 Sep 10;28(5):v511–v520.
   Google Scholar
• Gouverneur A, Salvo F, Berdai D, et al. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: a systemic review. J Geriatr Oncol. 2018 Jan;9(1):15–23. PMID: 28844343.
   PubMed Web of Science ®Google Scholar
• Le Saux O, Falandry C, Gan HK, et al. Inclusion of elderly patients in oncology clinical trials. Ann Oncol. 2016 Sep;27(9):1799–1804. PMID: 27358382.
   PubMed Web of Science ®Google Scholar
• Soto-Perez-De-Celis E, Lichtman SM. Considerations for clinical trial design in older adults with cancer. Expert Opin Investig Drugs. 2017 Oct;26(10):1099–1102. PMID: 2881418.
   PubMed Web of Science ®Google Scholar
• Le Saux O, Falandry C, Gan HK, et al. Changes in the use of comprehensive geriatric assessment in clinical trials for older patients with cancer over time. Oncologist. 2019 Feb 1:pii:theoncologist.2018–0493. PMID: 30710065. doi:10.1634/theoncologist.2018-0493
   PubMed Web of Science ®Google Scholar
• Dotan E, Browner I, Hurria A, et al. Challenges in the management of older patients with colon cancer. J Natl Compr Cancer Netw. 2012 Feb;10(2):213–224. PMID: 22308516.
   PubMed Web of Science ®Google Scholar
• Kenis C, Wildiers H. Practice guideline: comprehensive geriatric assessment (cGA) in oncological patients. Int Soc Geriatric Oncol. 2011 July 20(1):4–102.
   Google Scholar
• SIOG International Society of Geriatric Oncology. Comprehensive geriatric assessment (CGA) of the older patients with cancer. [ cited 2019 May 17]. Available from: http://www.siog.org/content/comprehensive-geriatric-assessment-cga-older-patient-cancer
   Google Scholar
• Mohile SG, Fan L, Reeve E, et al. Association of cancer with geriatric syndromes in older Medicare beneficiaries. J Clin Oncol. 2011 Apr 10;29(11):1458–1464. PMID: 21402608.
   PubMed Web of Science ®Google Scholar
• Ethun CG, Bilen MA, Jani AB, et al. Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin. 2017 Sep;67(5):362–377. PMID: 28731537.
   PubMed Web of Science ®Google Scholar
• Overcash J, Cope DG, Van Cleave JH. Frailty in older adults: assessment, support, and treatment implications in patients with cancer. Clin J Oncol Nurs. 2018 Dec 1;22(6):8–18.
   PubMed Web of Science ®Google Scholar
• Ruffinelli Rodriguez JC, Soler G, Legido M, et al. Detection of frailty in elderly colorectal cancer patients: is G8 a good screening tool? Ann Oncol. 2018 Oct 21;29(suppl_8):viii150–viii204.
   Google Scholar
• Ommundsen N, Wyller TB, Nesbakken A, et al. Frailty is an independent predictor of survival in older patients with colorectal cancer. Oncologist. 2014 Dec;19(12):1268–1275. PMID: 25355846.
   PubMed Web of Science ®Google Scholar
• Boakye D, Rillmann B, Walter V, et al. Impact of comorbidity and frailty on prognosis in colorectal cancer patients: a systematic review and meta-analysis. Cancer Treat Rev. 2018 Mar;64:30–39. PMID: 29459248.
   PubMed Web of Science ®Google Scholar
• Pendergrass JC, Targum SD, Harrison JE. Cognitive impairment associated with cancer: a brief review. Innov Clin Neurosci. 2018 Feb 1;15(1–2):36–44. PMID: 29497579.
   PubMedGoogle Scholar
• Shachar SS, Willaims GR. The obesity paradox in cancer-moving beyond BMI. Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):13–16. PMID: 28069727.
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. Clin Oncol J. 2011 Sep 1;29(25):3457–3465. PMID: 21810685.
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 2012 Jul 1;118(13):3377–3386. PMID: 22072065.
   PubMed Web of Science ®Google Scholar
• Hersh LR, Beldowski K, Hajjar ER. Polypharmacy in the geriatric oncology population. Curr Oncol Rep. 2017 Sep 23;19(11):73. PMID: 28942563.
   PubMed Web of Science ®Google Scholar
• Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507–522. PMID: 20418534.
   PubMed Web of Science ®Google Scholar
• Chu MP, Hecht JR, Slamon D, et al. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2017 Jun 1;3(6):767–773. PMID: 27737436.
   PubMed Web of Science ®Google Scholar
• Braftovi (encorafenib) package insert. Boulder, CO: Array BioPharma Inc.; 2019 Jan.
   Google Scholar
• Mektovi (binimetinib) package insert. Boulder, CO: Array BioPharma Inc; 2019 Jan.
   Google Scholar
• Tafinlar (dabrafenib) package insert. East Hanover, New Jersey: Novartis; 2018 May.
   Google Scholar
• Mekinist (trametinib) package insert. East Hanover, New Jersey: Novartis; 2018 May.
   Google Scholar
• Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J. 2012 Aug;105(8):437–445. PMID: 22864103.
   PubMed Web of Science ®Google Scholar
• McCleary NJ, Dotan E, Browner I, et al. Refining the chemotherapy approach for older patients with colon cancer. J Clin Oncol. 2014 Aug 20;32(24):2570–2580. PMID: 25071118.
   Google Scholar
• Marosi C, Koller M. Challenges of cancer in the elderly. ESMO Open. 2016 Apr 12;1(3):e000020. PMID: 27843603.
   PubMed Web of Science ®Google Scholar
• 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American geriatrics society beers criteria ® Update expert panel. American geriatrics society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019 Apr;67(4):679–694. PMID: 30693946.
   Web of Science ®Google Scholar
• U.S. Food & Drug Administration. Statement from FDA commissioner Scott Gottlieb, M.D., on the agency’s new efforts to strengthen regulation of dietary supplements by modernizing and reforming FDA’s oversight. Release date: February 11, 2019.
   Google Scholar
• Centers for Disease Control and Prevention. Division for Heart Disease and Stroke Prevention. Community pharmacist and medication therapy management. 2018 Jan 16.
   Google Scholar
• Bertsch NS, Bindler RJ, Wilson PL, et al. Medication therapy management for patients receiving oral chemotherapy agents at a community oncology cancer: a pilot study. Hosp Pharm. 2016 Oct;51(9):721–729. PMID: 27803501.
   PubMedGoogle Scholar
• Chan M, Hugh-Yeun K, Gresham G, et al. Population-based patterns and factors associated with underuse of palliative systemic therapy in elderly patients with metastatic colon cancer. Clin Colorectal Cancer. 2017 Jun;16(2):147–153. PMID: 27670894.
   PubMed Web of Science ®Google Scholar
• Grande R, Natoli C, Ciancola F, et al. Treatment of metastatic colorectal cancer patients ≥ 75 years old in clinical practice: a multicenter analysis. PLoS One. 2016 Jul 21;11(7):e0157751. PMID: 27442239.
   PubMed Web of Science ®Google Scholar
• Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: international society of geriatric oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015 Mar;26(3):463–476. PMID: 25015334.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004 Sep;15(9):1330–1338. PMID: 15319237.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label randomized factorial trial. Lancet. 2011 May 21;377(9779):1749–1759. PMID: 21570111.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol. 2016 Jan;27(1):121–127. PMID: 26487578.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Jouve JL, Teillet L, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. Clin Oncol J. 2013 Apr 10;31(11):1464–1470. PMID: 23460711.
   PubMed Web of Science ®Google Scholar
• Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer. 2010 May 11;102(10):1468–1473. PMID: 20424611.
   PubMed Web of Science ®Google Scholar
• Francois E, Smith DM, Gourgou S, et al. Bevacizumab combined with first-line chemotherapy in elderly patients (≥ 75 years old) with metastatic colorectal cancer: final results of the noninterventional CASSIOPEE study. J Clin Oncol. 2017 May 20;35(15):3547.
   Google Scholar
• Francois E, Kim SCH, Burki F, et al. Bevacizumab plus chemotherapy as first-line therapy for elderly patients with metastatic colorectal cancer interim results of the noninterventional CASSIOPEE study. J Clin Onc. 2016 May 20;34(15):3555.
   Google Scholar
• Obermannova R, Van Cutsem E, Yoshino T, et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 2016 Nov;27(11):2082–2090. PMID: 27573561.
   PubMed Web of Science ®Google Scholar
• Ruff P, Van Cutsem E, Lakomy R, et al. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: an age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol. 2018 Jan;9(1):32–39. PMID: 28807738.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. First-line combination of capecitabine and oxaliplatin plus bevacizumab in elderly patients with metastatic colorectal cancer (COBRA). [ cited 2019 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03451370
   Google Scholar
• Rosati G, Aprile G, Cardellino GG, et al. A review and assesment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2016 Mar;7(2):134–141. PMID: 26897044.
   PubMed Web of Science ®Google Scholar
• Tabemero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist. 2008 Feb;13(2):113–119. PMID: 18305055.
   PubMed Web of Science ®Google Scholar
• Chinuki Y, Morita E. Alpha-Gal-containing biologics and anaphylaxis. Allergol Int. 2019 Jul;68(3):296–300. Epub 2019 Apr 30. PMID: 31053502.
   PubMed Web of Science ®Google Scholar
• Feliu J, Salud A, Losada EP, et al. First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial. J Clin Onc. 2018 Jun 1;36(15_suppl). DOI:10.1200/JCO.2018.36.15_suppl.TPS3618
   Web of Science ®Google Scholar
• Clinicaltrials.gov. Study of I line FOLFOX + panitumumab vs. 5-FU + panitumumab in RAS and BRAF WT metastatic colorectal cancer elderly patients. [ cited 2019 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02904031
   Google Scholar
• Van Cutsem E, Sobrero A, Siena S, et al. REgorafenib (REG) in progressive metastatic colorectal cancer (mCRC): analysis of age subroups in the phase III CORRECT trial. J Clin Onc. 2013 May 20;31(15):3636.
   Google Scholar
• Van Cutsem E, Mayer RJ, Laurent S, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorecatl cancer. Eur J Cancer. 2018 Feb;90:63–72.
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab TS, Ou FS, Anderson DM, et al. Regorafenib dose optimization study (ReDOS): randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) an ACCRU network study. J Clin Oncol. 2018 Feb 1;36(4):611.
   Google Scholar
• Petrioli R, Chirra M, Mesuti L, et al. Efficacy and safety of regorafenib with 2/1 schedule for patients ≥ 75 years with metastatic colorectal cancer (mCRC) after failure of 2 lines of chemotherapy. Clin Colorectal Cancer. 2018 Dec;17(4):307–312. PMID: 29548772.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Hochster HS, Cohen SJ, et al. Safety of trifluridine/tipiracil in an open-label expanded –access program in elderly and younder patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2018 Dec;82(6):961–969.
   PubMed Web of Science ®Google Scholar
• Kanesvaran R, Cordoba R, Maggiore R, et al. Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research. Am Soc Clin Oncol Educ Book. 2018 May 23;400–414. DOI:10.1200/EDBK_201435.
   PubMedGoogle Scholar
• Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell carcinoma (RAMONA). BMC Cancer. 2019 Mar 14;19(1):231. PMID: 30871493.
   PubMedGoogle Scholar
• Kopetz S, McDonough SL, Morris VK, et al. Randomized trial of irintoecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol. 2017 Feb 1;35(4):520.
   Web of Science ®Google Scholar
• Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therpay for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol. 2019 Mar 20. PMID: 30892987. doi:10.1200/JCO.18.02459.
   PubMedGoogle Scholar
• Levit LA, Singh H, Klepin HD, et al. Expanding the evidence base in geriatric oncology: action items from an FDA-ASCO workshop. J Natl Cancer Inst. 2018 Nov 1;110(11):1163–1170. PMID: 30329076.
   PubMedGoogle Scholar
• Freedman RA, Dockter TJ, Lafky JM, et al. Promoting accrual of older patients with cancer to clinical trials. An alliance for clinical trials in oncology member survery (A171602). Oncologist. 2018 Sep;23(9):1016–1023. PMID: 29674441.
   PubMed Web of Science ®Google Scholar
• Baldini C, Mourey L, Liposits G. Perspectives on geriatric oncology research presented at the 2018 European society of medical oncology: young international society of geriatric oncology report. J Geriatric Onc. 2019 Mar;10(2):183–185.
   PubMed Web of Science ®Google Scholar
• Soto-Perez-de-Celis E, Loh K. Perspectives on geriatric oncology research presented at the 2018 American society of clinical oncology annual meeting. J Geriatr Oncol. 2018 Sep;9(5):419–422. PMID: 30005981
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Quality of life in elderly patients with metastatic colorectal cancer receiving first-line therapy based on simplified geriatric parameters (COLAGE). [ cited 2019 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03828227.
   Google Scholar
• Clinicaltrials.gov. Colon cancer elderly. [ cited 2019 May 17]. Available from: https://clinicaltrials.gov/ct2/results?cond=Colon+Cancer+elderly&term=&cntry=&state=&city=&dist
   Google Scholar